Oksana Koneva

AQRT to double TAM with Phase 2 Vitiligo study in $1 billion market, Michael Taylor notes

AQRT to double TAM with Phase 2 Vitiligo study in $1 billion market, Michael Taylor notes
AQRT plans Vitiligo study 4Q26

Michael Taylor, co-founder / portfolio manager at Agora Trading, highlights that AQRT has a planned Phase 2 go/nogo study for Vitiligo, an autoimmune pigmenting disorder, set for 4Q26.

Taylor notes that this represents a $1 billion market and could double AQRT’s total addressable market compared to ZORYVE topical, with the market currently not pricing in this potential.

Taylor previously identified FJET as a little-known bear trade opportunity earlier this year. He also projected that the U.S. Federal Reserve could enact multiple interest rate cuts in 2027, citing factors like lower energy costs in a separate report on Fed policy expectations. These past assessments reflect Taylor’s ongoing focus on emerging trends and under-recognized market developments.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.